Oncology Newswire

Live Results

1 - Curves Joins Breast Cancer Awareness Campaign

WACO, Texas-(Business Wire)-September 29, 2009 - The probability of a woman being diagnosed with invasive breast cancer during her life is about one in eight. And, the probability of dying from breast cancer is about one in 35, according to the American Cancer Society. Breast cancer death rates...

2 - MannKind to Present at the Fourth Annual JMP Securities Healthcare Focus Conference

VALENCIA, Calif.-(Business Wire)-September 29, 2009 - MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Fourth Annual JMP Securities Healthcare Focus Conference on Tuesday...

3 - SATAI Announces $1.045 Million Emerging Technology Fund Investment in Azaya Therapeutics, Inc.

SAN ANTONIO-(Business Wire)-September 29, 2009 - SATAI (www.satai.us) and the South Texas Regional Center of Innovation and Commercialization (www.strcic.com) today announced an investment of $1.045 million in Azaya Therapeutics, Inc. through the Texas Emerging Technology Fund (ETF) for the...

4 - Personalized, Gene-Based Risk Testing For Lung Cancer Gives New Tool To Help Smokers Quit

PHILADELPHIA-(Business Wire)-September 29, 2009 - Smokers who learn their personal risk of lung cancer through gene-based risk assessment are more likely to be motivated to quit their habit, according to Dr. W. Jeffrey Allard, clinical affairs director of Synergenz Bioscience Ltd. The...

5 - Clinical Data, Inc. to Present at the JMP Securities Healthcare Focus Conference

NEWTON, Mass.-(Business Wire)-September 29, 2009 - Clinical Data, Inc. (NASDAQ: CLDA), today announced that Drew Fromkin, President and Chief Executive Officer, will be presenting a corporate overview at the Fourth Annual JMP Securities Healthcare Focus Conference. Clinical Data's presentation...

6 - Rosetta Genomics to Present at the 2009 Maxim Group Growth Conference

PHILADELPHIA & REHOVOT, Israel-(Business Wire)-September 29, 2009 - Rosetta Genomics, Ltd. (NASDAQ:ROSG) a leading developer of microRNA-based molecular diagnostics, announced that management will present a corporate update at the 2009 Maxim Group Growth Conference today, Tuesday, September...

7 - Todd Cancer Institute at Long Beach Memorial Medical Center and Miller Children’s Hospital Granted Approval for Proton Therapy Project

LONG BEACH, Calif.-(Business Wire)-September 29, 2009 - The Todd Cancer Institute (TCI) at Long Beach Memorial Medical Center (LBMMC) and Miller Children’s Hospital (MCH) today announced it has been granted approval to proceed with the architecture and engineering for its proton therapy center...

8 - Susan G. Komen for the Cure® and the Susan G. Komen for the Cure® Advocacy Alliance Tap Jennifer Luray to Lead Public Policy Efforts

WASHINGTON, D.C.-(Business Wire)-September 29, 2009 - Jennifer M. Luray, a well-respected government affairs and public policy leader with extensive health care experience and strong ties to both Capitol Hill and the executive branch, has been named Vice President of Government Affairs and Public...

9 - Court Rules in Favor of Bard in Class Action Lawsuit

MURRAY HILL, N.J.-(Business Wire)-September 29, 2009 - C. R. Bard, Inc. (NYSE: BCR) today announced that the U.S. District Court, Eastern District of Missouri, has granted Bard's summary judgment motion and dismissed with prejudice all counts in the previously-disclosed class action lawsuit entitled...

10 - CPRIT Announces Release of Two Prevention Funding Opportunities

AUSTIN, Texas-(Business Wire)-September 29, 2009 - The Cancer Prevention and Research Institute of Texas (CPRIT) has released its first two cancer prevention requests for applications (RFA) just six weeks after Rebecca Garcia, Ph.D. joined CPRIT’s leadership team as chief prevention officer...

11 - Comcast Launches Third Annual Pink Ribbon Campaign

PHILADELPHIA-(Business Wire)-September 29, 2009 - Comcast Corporation (Nasdaq:CMCSA, CMCSK) today launched its third annual Pink Ribbon campaign, a unique multiplatform initiative to raise awareness and better educate women, their families and friends about breast cancer. The video-on-demand and...

12 - Plexxikon Announces First Patient Dosed in First of Two Pivotal Trials of PLX4032 for Metastatic Melanoma

BERKELEY, Calif.-(Business Wire)-September 29, 2009 - Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug...

13 - Novelos Therapeutics Announces $1 Million NIH Grant to MGH to Study NOV-002 and NOV-205 In Animal Models of Radiation-Induced Lung Injury

NEWTON, Mass.-(Business Wire)-September 29, 2009 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the Massachusetts General Hospital (MGH), in collaboration with Novelos, was awarded...

14 - BSD Medical Corporation Sells Hyperthermia System to University of California, San Francisco Medical Center

SALT LAKE CITY-(Business Wire)-September 29, 2009 - BSD Medical Corporation (NASDAQ: BSDM) (www.BSDMedical.com) announced today that the University of California, San Francisco Medical Center (UCSF) has acquired a BSD-500 Hyperthermia System (BSD-500). UCSF is a world leader in hyperthermia and...

15 - Computable Genomix Announces Contest For Genomics Researchers

MEMPHIS, Tenn.-(Business Wire)-September 29, 2009 - Memphis-based Computable Genomix today announced it will launch a contest on Oct. 1, 2009, to coincide with the release of GeneIndexer, the company’s next-generation Web-based text-mining tool. Publish or Perish will award a $10,000 grant to each...

16 - SAIC-Frederick and Roche Enter into a Research Collaboration on Technology Advancements for Cancer Gene Sequencing

MADISON, Wis.-(Business Wire)-September 29, 2009 - National Cancer Institute contractor SAIC-Frederick, Inc., a wholly owned subsidiary of Science Applications International Corporation (NYSE: SAI), and Roche Applied Science, a division of Roche Diagnostics Corporation (SWX:RO) (SWX:ROG) (Pink...

17 - Aurora Breast MRI of Sarasota and Clear Channel Radio, Partner for “Change for Change” Fundraising Event

SARASOTA, Fla.-(Business Wire)-September 29, 2009 - Aurora Breast MRI of Sarasota today announced it has partnered with Clear Channel Radio for a fundraising effort to benefit The Wellness Community of Southwest Florida. The fundraiser, titled “Change for Change,” will consist of a series of...

18 - State Farm Receives CEO Cancer Gold StandardTM Accreditation

CARY, N.C.-(Business Wire)-September 29, 2009 - State Farm has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy...

19 - Seattle Cancer Care Alliance, ProCure to Develop Proton Therapy Center

SEATTLE & BLOOMINGTON, Ind.-(Business Wire)-September 29, 2009 - The development of a proton therapy center in the Pacific Northwest has taken a significant step forward with the signing of a letter of intent between the Seattle Cancer Care Alliance (SCCA) and ProCure Treatment Centers Inc...

20 - Maxygen Announces Management Changes

REDWOOD CITY, Calif.-(Business Wire)-September 28, 2009 - Maxygen, Inc. (Nasdaq:MAXY) announced today that James Sulat, who currently serves as a director of the company, has been appointed to serve as Maxygen’s Chief Executive Officer, effective October 1, 2009. Mr. Sulat will replace Russell...

21 - Burzynski Research Institute Signs Research Agreement with the University of Alabama at Birmingham (UAB), Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility

HOUSTON-(Business Wire)-September 28, 2009 - The Burzynski Research Institute, Inc. (BRI) today announced that it has signed a Research Agreement with the UAB Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility (BBSF) that will provide biostatistical and data management...

22 - Research and Markets: Launching Next Generation Oncology Products as Market to Grow to US$75-80 billion by 2012: Evolving Strategies in a Payor's Market

DUBLIN-(Business Wire)-September 28, 2009 - Research and Markets . At the same time, success has come at a price. Not is the oncology marketplace getting more crowded, raising the bar for differentiation in a category in which many products are focusing on the same disease mechanisms, but the...

23 - PepsiAmericas Promotion Expects to Raise $50,000 for Breast Cancer Research

MINNEAPOLIS-(Business Wire)-September 28, 2009 - PepsiAmericas, Inc. (NYSE:PAS), the world's second-largest Pepsi bottler, announced today that it has joined the Lynn Sage Cancer Research Foundation in the effort to aid in national breast cancer research by releasing specially marked Pepsi® Pink...

24 - BioForward Announces Moderator, Panelists for Summit’s Final Plenary Session

MADISON, Wis.-(Business Wire)-September 28, 2009 - BioForward, the member-driven state association that is the voice of Wisconsin’s biotechnology industry, today announced moderator and panel participants for the closing plenary of the Biotechnology Vision Summit. The organization’s new...

25 - Arrival of 220-Ton Cyclotron Marks a Major Milestone in Construction of Illinois’ First Proton Therapy Center

WARRENVILLE, Ill.-(Business Wire)-September 28, 2009 - A 220-ton cyclotron, the core of what will soon be Illinois’ most advanced radiation treatment center, has ended a 5,000-mile journey that began in Belgium, arriving at the construction site of the CDH Proton Therapy Center, a ProCure...

26 - iCAD to Present at America’s Growth Capital 6th Annual East Coast Emerging Growth Conference

NASHUA, N.H.-(Business Wire)-September 28, 2009 - iCAD, Inc. (NASDAQ: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced that Ken Ferry, President and Chief Executive Officer and Darlene Deptula-Hicks...

27 - IsoRay Announces Cornell Medical Center Adopts Cesium-131 to Treat Head and Neck Cancer

RICHLAND, Wash.-(Business Wire)-September 28, 2009 - IsoRay, Inc. (Amex: ISR) announced today that on August 5, 2009, Dr. Bhupesh Parashar from the Department of Radiation Oncology, Dr. David Kutler of the Department of Otorhinolaryngology, and Dr. Jason Spector of the Department of Plastic...

28 - Celsion Corporation Announces $7.1 Million Registered Direct Offering

COLUMBIA, Md.-(Business Wire)-September 28, 2009 - Celsion Corporation (the “Company”) (NASDAQ: CLSN), an innovative oncology drug development company dedicated to the development and commercialization of innovative oncology drugs, today announced that it has entered into definitive agreements...

29 - EARLY Act Congressional Event Highlights Breast Cancer Risk Assessment

WASHINGTON-(Business Wire)-September 28, 2009 - Testing for breast cancer risk was the subject of remarks by two featured speakers at a recent congressional reception on Capitol Hill. The event generated momentum to pass the EARLY Act and raise awareness about breast cancer in young adult women...

30 - Saint John’s Health Center Appoints Internationally Recognized Neurosurgeon

SANTA MONICA, Calif.-(Business Wire)-September 28, 2009 - Saint John’s Health Center today announced the appointment of world-renowned neurosurgeon Amin Kassam, MD, as Director of the new Saint John’s Neuroscience Institute and faculty member of the John Wayne Cancer Institute at Saint John’s...

31 - Helicos Announces System Sale to Correlagen Diagnostics

CAMBRIDGE, Mass.-(Business Wire)-September 28, 2009 - Helicos BioSciences Corporation (NASDAQ: HLCS) today announced the sale of a system and a scientific collaboration with Correlagen Diagnostics Inc., a leading provider of genetic tests for disease diagnosis. “We are very excited to have...

32 - Life Technologies and febit Team to Offer New Solution for Targeted Re-sequencing in Large-scale Genomic Studies

CARLSBAD, Calif. & HEIDELBERG, Germany-(Business Wire)-September 28, 2009 - febit holding GmbH and Life Technologies Corporation (NASDAQ: LIFE) today announced that they have entered into a strategic co-marketing agreement to provide a new, scalable solution for researchers conducting targeted...

33 - Inovio Biomedical to Present at Vaccine 3rd Global Congress

SAN DIEGO-(Business Wire)-September 28, 2009 - Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today it will make multiple presentations at the Vaccine 3rd Global Congress being held in Singapore October 4th – 6th. Inovio...

34 - Photos of Sarah Chalke Supporting Breast Cancer Awareness Available on Business Wire's Web Site and AP PhotoExpress

-(Business Wire)-September 27, 2009 - Actress Sarah Chalke attends Susan G. Komen Orange County Race for the Cure®. Photo one: (race 4) Actress Sarah Chalke (right), ambassador for the Susan G. Komen Passionately Pink for the Cure® program, and Dr. Lisa Guerra (left), a breast surgeon and board...

35 - UPDATE on Advisory/New Satellite Coordinates for New World Record for Female Formation Skydive to Benefit Breast Cancer Awareness

-(Business Wire)-September 27, 2009 - Jump for the Cause wishes to issue the following update to its release NewsItemID 20090927005029 (CA-JUMP-FOR-THE-CAUSE) "Advisory/Satellite Coordinates for New World Record for Female Formation Skydive to Benefit Breast Cancer Awareness" issued earlier...

36 - Advisory/Satellite Coordinates for New World Record for Female Formation Skydive to Benefit Breast Cancer Awareness

-(Business Wire)-September 27, 2009 - Jump for the Cause: Who:     181 female skydivers from 31 countries joined together on September 26 at 1:30 p.m. Pacific Time to set a new women's formation sky diving world record and raise more than $900,000 for the fight against breast cancer, the most in...

37 - 181 Women Jump for the Cause and Set New World Record Formation Skydive to Fight Breast Cancer

PERRIS, Calif.-(Business Wire)-September 26, 2009 - 181 female skydivers from 31 countries joined together on Sept 25 at 1:30 p.m. Pacific Time to set a new women’s formation skydiving world record and raise over $900,000 for the fight against breast cancer, the most in the event’s history...

38 - Positron Anticipates Cardiac PET Demand to Increase Due to Expanding Reimbursment Differential Between PET and SPECT Imaging

INDIANAPOLIS-(Business Wire)-September 25, 2009 - Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused on Nuclear Cardiology, predicts a significant rise in demand for Cardiac PET in 2010 with a proposed cut in SPECT reimbursement of 46% and an increase in PET...

39 - Idera Pharmaceuticals Presents Final Data from Phase 2 Clinical Trial of IMO-2055 Monotherapy in Renal Cell Carcinoma

CAMBRIDGE, Mass.-(Business Wire)-September 25, 2009 - Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced the presentation of final data from a clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as monotherapy in patients with Renal Cell Carcinoma (RCC). The data...

40 - Advaxis Secures $5.0 Million Investment

NORTH BRUNSWICK, N.J.-(Business Wire)-September 25, 2009 - Advaxis, Inc. (OTCBB: ADXS), has entered into a definitive agreement for a $5 million investment commitment (the “Investment”) with an investment fund (the “Investor”). “This financing, combined with our current debt offering, will...

41 - Altor BioScience Awarded $3 MM SBIR Bridge Grant by NCI to Advance Clinical Trials for its Targeted Cancer Therapeutic ALT-801

MIRAMAR, Fla.-(Business Wire)-September 25, 2009 - Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II Bridge Grant by the National Cancer Institute (NCI). The award of $3 MM over three years will help Altor further its...

42 - Dyax Corp. to Present at the JMP Securities Healthcare Focus Conference

CAMBRIDGE, Mass.-(Business Wire)-September 25, 2009 - Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A. Christensen, President and Chief Executive Officer of Dyax, will present at the Fourth Annual JMP Securities Healthcare Focus...

43 - Allos Therapeutics’ FOLOTYN™ First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma

WESTMINSTER, Colo.-(Business Wire)-September 25, 2009 - Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYNTM (pralatrexate injection) for use as a single agent for the treatment of patients...

44 - Massage Envy® Provides Over 46,000 Massages During National Event

SCOTTSDALE, Ariz.-(Business Wire)-September 25, 2009 - Massage Envy’s (www.massageenvy.com) annual signature fundraising event, Massage for the Cure, provided an unprecedented 46,680 massages and raised over $466,000 during the nationwide event. Massage for the Cure, hosted on Tuesday, September...

45 - A-Life Medical, Inc. to Exhibit at the American College of Emergency Physician (ACEP) Scientific Assembly

WHO:   A-Life Medical, Inc., the pioneer in and leading provider of computer-assisted coding (CAC) products and services for the healthcare industry.   WHAT: A-Life Medical to Showcase its CAC Capabilities to the Emergency Medicine Marketplace at leading industry trade association platform...

46 - pSivida Corp. Reports Results for the Fourth Quarter and Fiscal Year Ended June 30, 2009

WATERTOWN, Mass.-(Business Wire)-September 24, 2009 - pSivida Corp. (NASDAQ: PSDV) (ASX: PVA) (FF: PV3), a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back of the eye diseases, today announced financial...

47 - Advaxis Cures Late Form 10-Q Filing

NORTH BRUNSWICK, N.J.-(Business Wire)-September 24, 2009 - Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, announced today that the Company's ticker symbol has been temporarily changed to ADXSE denoting untimely filing of the Company’s July 31, 2009...

48 - Arizona Residents Greg and Lauren Glassman Recognized for Their Support in Fighting Cancer

SANTA MONICA, Calif.-(Business Wire)-September 24, 2009 - Greg and Lauren Glassman, founders of CrossFit, Inc., are providing crucial funding for the battle against prostate cancer. In acknowledgement of CrossFit’s annual Fight Gone Bad event that has raised more than $1 million since 2006, the...

49 - Imprime PGG® Named a Top 10 Oncology Drug Candidate for Partnering

EAGAN, Minn.-(Business Wire)-September 24, 2009 - Biothera, a privately held biotechnology company, announced today that its lead drug candidate, Imprime PGG®, has been named one of the Top 10 Most Interesting Oncology Projects Available for Partnering by Windhover Information Inc. in conjunction...

50 - Susan G. Komen Races for the Cure across Europe

WASHINGTON, D.C.-(Business Wire)-September 24, 2009 - A sea of pink t-shirts will stretch from Athens to Bologna to Frankfurt to Zurich to Antwerp today in an effort to raise public awareness about breast cancer. In five cities across Europe, breast cancer survivors, their families, friends...

51 - TRADE NEWS: Agilent Technologies, Shanghai Institute of Biological Sciences and Chinese Academy of Sciences Open Center for Systems Biology

SANTA CLARA, Calif. & SHANGHAI-(Business Wire)-September 24, 2009 - Agilent Technologies Inc. (NYSE:A) today announced the opening of the Shanghai Institute of Biological Sciences (SIBS)-Agilent Center for Systems Biology in Shanghai, China. The center will feature multiple technology...

52 - CEO Roundtable on Cancer Recognizes Aetna for Commitment to Improving the Health and Well-Being of Employees and Their Families

HARTFORD, Conn.-(Business Wire)-September 24, 2009 - The CEO Roundtable on Cancer today recognized Aetna (NYSE:AET) with a CEO Cancer Gold StandardTM accreditation for the company’s commitment to improving the health of employees and their families. To receive the accreditation, companies must...

53 - Research and Markets: Nuclear Oncology Covers Imaging, Dosimetric, And Therapeutic Applications of Radiopharmaceuticals and Metabolic Imaging Agents

DUBLIN-(Business Wire)-September 24, 2009 - Research and Markets. The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity...

54 - Health Discovery Corporation’s Dr. Stephen Barnhill Tells Participants at London Conference That Biomarkers Patented by His Company Promise to Revolutionize The Field of Molecular Diagnostics

SAVANNAH, Ga.-(Business Wire)-September 24, 2009 - Dr. Stephen Barnhill, Chairman and CEO, Health Discovery Corporation (OTCBB: HDVY) (“HDC”), a molecular diagnostics company, spoke at the “Biomarkers in Clinical Trials” Conference taking place in London, September 23-24, 2009. The...

55 - Genzyme’s Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia

CAMBRIDGE, Mass.-(Business Wire)-September 24, 2009 - Genzyme Corporation (Nasdaq: GENZ) announced today that its randomized Phase 3 clinical trial investigating Campath® (alemtuzumab) in combination with Fludara® (fludarabine phosphate) in relapsed or refractory chronic lymphocytic leukemia (CLL...

56 - IsoRay Inc. Announces Fiscal Year 2009 Results

RICHLAND, Wash.-(Business Wire)-September 24, 2009 - IsoRay Inc. (AMEX:ISR), a medical isotope company focused on the treatment of lung cancer, head and neck tumors, prostate cancer and other malignant disease through use of its proprietary radioisotope technology, announces today its financial...

57 - Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation

BERLIN-(Business Wire)-September 24, 2009 - Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC...

58 - BSD Medical Corporation Files $50 Million Shelf Registration

SALT LAKE CITY-(Business Wire)-September 24, 2009 - BSD Medical Corporation (NASDAQ:BSDM) (www.BSDMedical.com) today announced the filing of a shelf registration statement on Form S-3 with the Securities and Exchange Commission. The shelf registration statement, when declared effective by the...

59 - Global Prostate Cancer Research Meeting Opens

SANTA MONICA, Calif.-(Business Wire)-September 24, 2009 - Nearly of 300 of the world’s leading researchers focused on the problem of prostate cancer will begin a three-day meeting today to discuss the latest scientific data and breakthroughs in prostate cancer. The meeting, held in Incline Village...

60 - Pro-Pharmaceuticals to Present a Corporate Update at the Maxim Group Growth Conference

NEWTON, Mass.-(Business Wire)-September 24, 2009 - Pro-Pharmaceuticals, Inc. (OTC: PRWP) today announced that Theodore Zucconi, Ph.D., Chief Executive Officer, and James Czirr, Chairman of the Board, Pro-Pharmaceuticals, Inc., are scheduled to present a corporate update at the Maxim Group Growth...

61 - Perlegen Introduces BREVAGen™ Breast Cancer Risk Stratification Test

MOUNTAIN VIEW, Calif.-(Business Wire)-September 23, 2009 - Perlegen Sciences, which develops genetic tests that correlate genetic variation to disease risk and drug response, announced today that its BREVAGen™ breast cancer risk stratification test is now clinically available in select U.S...

62 - BioVectra Announces Oncolix Inc. Signs Manufacturing and Investment Agreement

CHARLOTTETOWN, PEI-(Business Wire)-September 23, 2009 - BioVectra, Inc., a cGMP manufacturing and development partner in Charlottetown, PEI, Canada, announces that it has reached an agreement with Oncolix Inc., a biopharmaceutical company based in Houston, Texas, to manufacture ProlantaTM for...

63 - LifeSensors, Inc. Obtains Worldwide, Exclusive License to High Affinity “Ubiquitin Traps”

MALVERN, Pa.-(Business Wire)-September 23, 2009 - LifeSensors, Inc., a biotechnology company specializing in protein expression technologies and ubiquitin pathway research tools, announced today their worldwide, exclusive license for high affinity ubiquitin traps. These new research tools, developed...

64 - Merck and QIAGEN Collaborate to Accelerate Access to Cervical Cancer Vaccination and Screening in Developing Countries

NEW YORK-(Business Wire)-September 23, 2009 - Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world. This initiative is the first time a vaccine...

65 - Genzyme Provides Update on Cerezyme and Fabrazyme Supply

CAMBRIDGE, Mass.-(Business Wire)-September 23, 2009 - Genzyme Corporation (NASDAQ: GENZ) today provided an update on its progress to restore supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) for patients worldwide and revised its 2009 revenue guidance for these...

66 - Bio-Matrix Scientific Group and Therinject LLC Begin Development of Tumor Banking Facility in Conjunction with Cancer Therapeutic Vaccine

SAN DIEGO-(Business Wire)-September 23, 2009 - Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN) announced today that the Company and Therinject LLC have begun development of a tumor banking facility. Tumor banking will allow storage and ease of sourcing for tumor cells to be utilized in cancer...

67 - Data Presented from Two Phase 3 ERBITUX® Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress

BERLIN-(Business Wire)-September 23, 2009 - According to a recent retrospective analysis of the pivotal Phase 3 CRYSTAL study, ERBITUX® (cetuximab), when added to FOLFIRI, was shown to increase median overall survival to 19.9 months in an intent-to-treat (ITT) population of first-line metastatic...

68 - Philips and Celsion Advance Development of ThermoDox® and MR-Guided HIFU

ANDOVER, Mass. & COLUMBIA, Md.-(Business Wire)-September 23, 2009 - Royal Philips Electronics (NYSE: PHG; AEX: PHI) and Celsion Corporation (NASDAQ: CLSN) today announced that their joint research program to evaluate ThermoDox® in combination with MR-HIFU (Magnetic Resonance guided High...

69 - The International Myeloma Foundation to Hold Washington Meeting on Drug Regulation and Reimbursement to Make Health Reform Meaningful and Cost-Effective for Patients with Rare Cancers

NORTH HOLLYWOOD, Calif.-(Business Wire)-September 23, 2009 - The International Myeloma Foundation (IMF)—supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians—today said health reform must move beyond the current government...

70 - GE Healthcare Launches Global Initiative to Celebrate 10th Anniversary of Digital Mammography

BUC, France-(Business Wire)-September 23, 2009 - In addition to being Breast Cancer Awareness Month, this October is the tenth anniversary of digital mammography, a technology introduced by GE Healthcare (NYSE:GE) in 1999. Similar to digital photography, digital mammography replaces the film used in...

71 - Idera Pharmaceuticals Presents Interim Data from Phase 1b Clinical Trial of IMO-2055 in Combination with Tarceva® and Avastin® in Non-Small Cell Lung Cancer

CAMBRIDGE, Mass.-(Business Wire)-September 23, 2009 - Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small...

72 - Plexxikon Announces Encouraging Data from Phase 1 Extension Study of PLX4032 Showing Objective Responses in Metastatic Melanoma Patients

BERLIN, Germany & BERKELEY, Calif.-(Business Wire)-September 23, 2009 - Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032...

73 - Miley Cyrus, Demi Lovato and Jesse McCartney to Perform at Second Annual Concert for Hope Presented by Staples, Inc., October 25 at Nokia Theatre L.A. LIVE

LOS ANGELES-(Business Wire)-September 22, 2009 - Disney Music Group artists Miley Cyrus, Demi Lovato and Jesse McCartney will hit all the right notes in the fight against cancer when they take the stage at the second annual Concert for Hope presented by Staples, Inc. on Sunday, October 25, it was...

74 - Spectrum Pharmaceuticals Receives $50 Million from Institutional Investors at $7.55 Per Share

IRVINE, Calif.-(Business Wire)-September 22, 2009 - Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus primarily in oncology, today announced that it has received $50 million from existing institutional investors in a previously announced registered...

75 - Susan G. Komen for the Cure® Founder Nancy G. Brinker Warns of Coming Global Cancer Crisis; Calls on World Leaders at United Nations to “Include Cancer” on Health Agendas

NEW YORK-(Business Wire)-September 22, 2009 - The leader of the global breast cancer movement today warned of a coming wave of cancer deaths and told global health ministers to be “fearless and united” in addressing the growing cancer crisis, particularly in developing countries. “Cancer takes...

76 - BioSante Pharmaceuticals and Cell Genesys Announce Final Exchange Ratio for Merger

LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 22, 2009 - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Cell Genesys, Inc. (NASDAQ: CEGE), today announced that they have determined the final exchange ratio as 0.1828 in connection with the previously announced...

77 - BioAlliance Pharma Announces That the Civil Action Filed by Eurofins in the United States is Rejected

Regulatory News: BioAlliance Pharma SA (Paris:BIO) announces today that the American District Judge has granted the motion to dismiss of BioAlliance Pharma and one of its executive in response to the civil action filed by Eurofins. Eurofins filed an appeal. In 2008, Eurofins Pharma US Holding Inc...

78 - Bio-Path Holdings, Inc. Announces Plans to Develop Liposome Tumor Targeting Technology Licensed from The University of Texas M. D. Anderson Cancer Center

HOUSTON-(Business Wire)-September 22, 2009 - Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center to...

79 - Secretary Sebelius Joins NCAA Basketball Coaches to Rally for Health Insurance Reform

WASHINGTON-(Business Wire)-September 22, 2009 - HHS Secretary Kathleen Sebelius today joined five NCAA Division I basketball coaches, Senators Robert Casey, Al Franken and Amy Klobuchar, and cancer survivors and advocates from the American Cancer Society Cancer Action Network to rally in support...

80 - MagForce Nanotechnologies Completes Patient Recruitment for Pivotal Glioblastoma Study

BERLIN-(Business Wire)-September 22, 2009 - MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer® therapy. The results of this...

81 - Research and Markets: Lynn Sage Breast Cancer Symposium - a Forum of Discussions and Presentations in Laboratory and Clinical Research Concerning the Care of Patients with Breast Cancer

DUBLIN-(Business Wire)-September 22, 2009 - Research and Markets . Physicians should only claim credit commensurate with the extent of their participation in the activity. Date of Original Release: December 31, 2008 Termination Date: January 1, 2012 For more information on the topics covered and...

82 - Altos Solutions and Oncology Metrics Plan Merger

LOS ALTOS, Calif.-(Business Wire)-September 22, 2009 - Altos Solutions and Oncology Metrics llc, today announced the planned merger of the two companies, creating a combined technology and knowledge data company serving community-based oncology practices. The merged company will be known as Altos...

83 - Baron & Budd, P.C. Sponsors CURE Media Group Book on Mesothelioma

DALLAS-(Business Wire)-September 22, 2009 - Baron & Budd, P.C. has sponsored the publication of a new informational book on mesothelioma titled Understanding Mesothelioma. Understanding Mesothelioma was published by CURE Media Group, L.P., which also publishes CURE, a magazine dedicated to...

84 - Cancer Patients Not Given Adequate Information on Fertility Preservation

CHICAGO-(Business Wire)-September 22, 2009 - Life-saving cancer treatments such as chemotherapy and radiation can destroy the reproductive potential of both men and women; an added struggle for the 130,000 people in the US diagnosed with cancer each year. The good news is that advances in...

85 - Barclays/Nets Community Alliance Partners with Camp Sunshine to Support Hematology and Oncology Program

CASCO, Maine-(Business Wire)-September 22, 2009 - Today, Camp Sunshine announced it has received support from the Barclays/Nets Community Alliance, which includes a partnership among Barclays, the Nets and Forest City Ratner Companies. This support is enabling a special session at Casco, Maine based...

86 - Curis to Present at Maxim Group Growth Conference 2009

CAMBRIDGE, Mass.-(Business Wire)-September 22, 2009 - Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the Maxim Group Growth Conference...

87 - BSD Medical Reports News Briefing at Europe’s Largest Cancer Congress: Hyperthermia and Chemotherapy Treatment Prolongs Survival of Sarcoma Cancer Patients

SALT LAKE CITY-(Business Wire)-September 22, 2009 - BSD Medical Corporation (NASDAQ:BSDM) reports that significant and “medical practice changing” clinical study results were the subject of a news briefing at Europe’s largest cancer congress, ECCO15 – ESMO34, which is being held September 20...

88 - Helicos Presents at Cold Spring Harbor Laboratories Personal Genomes and CHI Next Generation Sequencing Meetings

CAMBRIDGE, Mass.-(Business Wire)-September 22, 2009 - Helicos BioSciences Corporation (NASDAQ: HLCS) provided updates on recent scientific findings and progress on Helicos’s technology initiatives. Speaking at the Personal Genomes conference in Cold Spring Harbor, NY, and the CHI Next Generation...

89 - Survival Benefit Maintained in Long Term Follow-up of IES with Pfizer’s AROMASIN® (Exemestane Tablets)

BERLIN-(Business Wire)-September 22, 2009 - Pfizer Inc today announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three years experienced a significant reduction (18%) in the...

90 - Research and Markets: Board Review in Medical Oncology

DUBLIN-(Business Wire)-September 22, 2009 - Research and Markets to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essential Areas, Elements and Policies. Credit Designation The George Washington University Medical Center...

91 - Singing Means Survival for Breast Cancer Victim

CHICAGO-(Business Wire)-September 21, 2009 - Breast cancer. These two words strike fear into the heart of every woman. Facing the challenge of breast cancer following a diagnosis is often overwhelming. For Marguerite Paustenbach, her secret weapon in the fight against breast cancer turned out to...

92 - HealthPort Launches New, Online Education Community for Health Information Management and Cancer Registry

ALPHARETTA, Ga.-(Business Wire)-September 21, 2009 - HealthPort, a top-25 company in the healthcare information technology industry, today announced an online healthcare education community specifically designed to meet the continuing education and professional development needs of health...

93 - Vertex Pharmaceuticals Employees Participate in First Companywide Day of Service

CAMBRIDGE, Mass., SAN DIEGO, OXFORDSHIRE, U.K. & CORALVILLE, Iowa-(Business Wire)-September 21, 2009 - Vertex Pharmaceuticals Incorporated today announced that approximately 800 employees took part in Vertex’s first companywide Day of Service, which was held on Friday, September 18, 2009. As...

94 - Mentor Capital, Inc. Completes 2nd Year Audit for OTCBB Move; Reporting $0.16 Per Share in Basic Earnings

SAN DIEGO-(Business Wire)-September 21, 2009 - Mentor Capital, Inc. (Pink Sheets:MNTR) completed its FY 2008 audit in preparation for filing a self-registration statement with the SEC and applying to move from the Pink Sheets to begin being quoted on the Over-the-Counter Bulletin Board system. The...

95 - Bio Nebraska Partners with Nebraska EPSCoR and University of Nebraska on 5th Annual Research and Innovation Conference in Omaha

OMAHA, Neb.-(Business Wire)-September 21, 2009 - Bio Nebraska Life Sciences Association, Nebraska EPSCoR and the University of Nebraska will host the 5th Annual Research and Innovation Conference on Tuesday, September 29, 2009 at the Qwest Center in Omaha. Registration begins at 7:30 a.m., and the...

96 - AngioDynamics to Hold Fiscal 2010 First Quarter Financial Results Conference Call on October 6, 2009

QUEENSBURY, N.Y.-(Business Wire)-September 21, 2009 - AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally-invasive treatment of cancer and peripheral vascular disease, announced today that it will report its...

97 - Women's Focus III, Breast Cancer Awareness Month Feature Release

SAN FRANCISCO-(Business Wire)-September 21, 2009 - The following release focuses on the topic Women's Focus III, Breast Cancer Awareness Month ALL TIME-OFFS ARE IN EASTERN TIME, UNLESS NOTED STORIES MOVED AT 4:35 AM ET ON SEPTEMBER 21, 2009. BOISE, Idaho—Wear Ease Designs the Latest Fashions...

98 - Advaxis Granted New Compositions and Methods Patent

NORTH BRUNSWICK, N.J.-(Business Wire)-September 21, 2009 - The United States Patent and Trademark Office (USPTO) has granted and issued Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, patent 7,588,930 “Compositions and Methods for Enhancing...

99 - Jump for the Cause and Perris Valley Skydiving Center Host Wounded Warriors

LOS ANGELES-(Business Wire)-September 21, 2009 - Jump for the Cause (www.jumpforthecause.com) will be celebrating the nation’s wounded warriors on Wednesday, September 23rd, at Perris Valley Skydiving Center (www.skydiveperris.com), Perris Valley, CA. The two organizations will host a dozen...

100 - Antigenics Announces Expansion of Its QS-21 License Agreement

LEXINGTON, Mass.-(Business Wire)-September 21, 2009 - Antigenics Inc. (NASDAQ: AGEN) today announced that the company has signed an amended and restated license agreement for the use of the QS-21 adjuvant in a vaccine under development by JANSSEN Alzheimer Immunotherapy, a company which has acquired...

101 - Sloning Closes Growth Financing Round Led by LBBW Venture

PUCHHEIM, Germany-(Business Wire)-September 21, 2009 - Sloning BioTechnology GmbH, the worldwide leading supplier of combinatorial gene libraries, received additional investments from all of its institutional shareholders: HBM BioVentures, LBBW Venture, DEWB and KfW to finance the company’s...

102 - Reportlinker Adds Launching Next Generation Oncology Products: Evolving Strategies in a Payor’s Market

NEW YORK-(Business Wire)-September 21, 2009 - Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Launching Next Generation Oncology Products: Evolving Strategies in a Payor’s Market...

103 - Carl’s Jr. and Hardee’s Achieve $1 Million Fundraising Goal in the Fight Against Breast Cancer

ST. LOUIS-(Business Wire)-September 21, 2009 - CKE Restaurants, Inc. today announced it has reached its goal of raising $1 million for breast cancer programs and awareness through its “Pink Star” fundraising campaign. During the three-week, in-store fundraiser that began in April, guests at...

104 - Rexahn Pharmaceuticals and Teva Pharmaceutical Industries Close on a License Agreement

ROCKVILLE, Md.-(Business Wire)-September 21, 2009 - Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced...

105 - Incyte Announces Positive Top-Line Phase IIb Results for Topical INCB18424 in Psoriasis

WILMINGTON, Del.-(Business Wire)-September 21, 2009 - Incyte Corporation (Nasdaq:INCY) announced positive clinical trial results for a topical formulation of its lead janus kinase (JAK) inhibitor, INCB18424, in psoriasis. These results were obtained from a multi-center three-month Phase IIb trial...

106 - PerkinElmer Launches Columbus™ 2.0 High Content Screening Platform for High-Volume Image Data Management and Analysis

BOSTON-(Business Wire)-September 21, 2009 - At the High Content Analysis East conference in Boston, PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced the launch of the Columbus™ 2.0 platform, its flagship high content...

107 - ARIAD Announces Clinical Data from Phase 1 Study of Its Investigational mTOR Inhibitor, Ridaforolimus, in Combination with Bevacizumab

CAMBRIDGE, Mass.-(Business Wire)-September 21, 2009 - ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced data from a Phase 1 clinical trial evaluating oral ridaforolimus, its investigational mTOR inhibitor, in combination with bevacizumab (Avastin®) in heavily pretreated patients with...

108 - Provectus Completes Treatment of All Patients in Phase 2 Trial of PV-10 for Metastatic Melanoma

KNOXVILLE, Tenn.-(Business Wire)-September 21, 2009 - Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical...

109 - Data Safety Monitoring Board Recommends Continuation of Celsion’s Phase III ThermoDox® Study for Primary Liver Cancer

COLUMBIA, Md.-(Business Wire)-September 21, 2009 - Celsion Corporation (NASDAQ:CLSN) announced today the Data Safety Monitoring Board (“DSMB”) has reviewed the safety data from the first group of patients enrolled in its pivotal ThermoDox® Phase III clinical trial for primary liver cancer...

110 - Semafore Retains Management Consulting Firm; Names Principal to Key Management Position

INDIANAPOLIS-(Business Wire)-September 21, 2009 - Semafore Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics targeting the phosphoinositide-3-kinase (PI3K) pathway for the treatment of cancer and other...

111 - David Bearss Resigns as Chief Scientific Officer to Join Huntsman Cancer Institute as Co-director of Center for Investigational Therapeutics

DUBLIN, Calif.-(Business Wire)-September 21, 2009 - SuperGen Inc. (Nasdaq:SUPG) announced that, effective October 16, 2009, David Bearss, Ph.D., will resign as SuperGen’s Chief Scientific Officer, and be engaged as a long-term biology consultant to the Company. In addition, Dr. Bearss will...

112 - Wear Ease Designs the Latest Fashions with Mastectomy Patients in Mind

BOISE, Idaho-(Business Wire)-September 21, 2009 - One in eight U.S. women will be diagnosed with breast cancer during their lifetime, and currently slightly more than half, 56 percent, undergo mastectomy. Few fashion options exist for those who don’t seek reconstructive surgery or postpone it...

113 - Rodman & Renshaw Exclusive Placement Agent for Spectrum Pharmaceuticals

NEW YORK-(Business Wire)-September 18, 2009 - Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), today announced that its client Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage biotechnology company with a focus in oncology, has received commitments from institutional...

114 - Metabasis Therapeutics Receives Notice of Noncompliance with Nasdaq Listing Requirements

SAN DIEGO-(Business Wire)-September 18, 2009 - Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that on September 15, 2009, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”), notifying the Company that based upon the closing...

115 - Zila Completes Merger With TOLMAR

SCOTTSDALE, Ariz.-(Business Wire)-September 18, 2009 - Zila, Inc. (Nasdaq: ZILA) today announced the completion of the merger with a subsidiary of TOLMAR Holding, Inc. Pursuant to the merger agreement between the companies, at the effective time of the merger all outstanding shares of Zila’s...

116 - Spectrum Pharmaceuticals to Raise up to $50 Million from Institutional Investors at $7.55 Per Share

IRVINE, Calif.-(Business Wire)-September 18, 2009 - Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced that it has received commitments from institutional investors to purchase $50 million of securities in a registered...

117 - Prostate Cancer Guide for African-American Men and Their Families Now Available

SANTA MONICA, Calif.-(Business Wire)-September 18, 2009 - A new guide, Straight Talk for African-American Men and their Families, is now available from the Prostate Cancer Foundation (PCF). It was produced in alliance with Charlie Wilson, famed R&B singer and recent prostate cancer survivor...

118 - Pfizer To Present Research On Established Therapies And New Approaches To Cancer Treatment Using Investigational Agents

NEW YORK-(Business Wire)-September 18, 2009 - Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer,1 updated study results from a Phase 3 study of Sutent® (sunitinib malate) in...

119 - Integrative Therapeutics, Inc. Seeking 2010 Residency Sites for STAIR Scholarship Program

GREEN BAY, Wis.-(Business Wire)-September 18, 2009 - Integrative Therapeutics, Inc (ITI®), in collaboration with the American Association of Naturopathic Physicians (AANP), is seeking qualified residency sites for the fourth year of the ITI & AANP STAIRSM Residency Scholarship Program. This...

120 - Research and Markets: EGF-R Agonists and Antagonists - A Competitor Evaluation in the Field of Epidermal Growth Factor Receptor Targeting Molecules for Wound Healing or Cancer Treatment

DUBLIN-(Business Wire)-September 18, 2009 - Research and Markets Celldex Therapeutics Chugai Curis Daewoong Pharmaceutical Co. Daiichi Sankyo ISU Abxis Jennerex Biotherapeutics Life Science Pharmaceuticals Med Discovery Medarex Merck Serono Micromet Oncalis Oncoscience Osi Pharmaceuticals Pfizer...

121 - FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE® (bortezomib) for Injection

CAMBRIDGE, Mass.-(Business Wire)-September 18, 2009 - Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall...

122 - BSD Medical Corporation Reports FDA Review of BSD-2000 Hyperthermia System Continues

SALT LAKE CITY-(Business Wire)-September 18, 2009 - BSD Medical Corporation (NASDAQ: BSDM) (www.bsdmedical.com) reported today that the U.S. Food and Drug Administration (FDA) continues its review of the Company's Humanitarian Device Exemption (HDE) marketing submission for the Company’s...

123 - Former Deputy FDA Commissioner John Norris Appointed Chief Operating Officer at Health Discovery Corporation

SAVANNAH, Ga.-(Business Wire)-September 18, 2009 - Health Discovery Corporation (OTCBB:HDVY), a personalized medicine company specializing in molecular diagnostics including gene-based testing, as well as computer assisted diagnostics in digital pathology and radiology, announced that former...

124 - Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences

CAMBRIDGE, Mass.-(Business Wire)-September 18, 2009 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the UBS Global Life Sciences Conference on Tuesday, September 22, 2009 at 2:30 p.m. EDT and at the JMP Securities Healthcare Conference...

125 - InSight Health Services Holdings Corp. Reports Results for the Fourth Quarter and Fiscal Year Ended June 30, 2009

LAKE FOREST, Calif.-(Business Wire)-September 17, 2009 - InSight Health Services Holdings Corp. (“InSight”) (OTCBB: ISGT) today announced its financial results for the fourth quarter and fiscal year ended June 30, 2009. Kip Hallman, InSight’s President and CEO, stated, “I am pleased that...

126 - Pancreatic and Colorectal Cancer Novel Antibody Developed from a Vaccine to Begin Phase I Trial

GREAT NECK, N.Y.-(Business Wire)-September 17, 2009 - Neogenix Oncology, Inc. (Neogenix) announced today that NPC-1C, the company’s first IND (Investigational New Drug Application) was granted permission by the Food and Drug Administration (FDA) for the company to begin a Phase I trial. NPC-1C...

127 - 3rd Annual Denver Cook for the Cure© to Be Held October 22, 2009

DENVER-(Business Wire)-September 17, 2009 - Cook for the Cure© on Thursday, October 22nd is a delicious way for breast cancer survivors and their supporters to help fight the battle against breast cancer while enjoying great food and fun cooking demonstrations. This one-of-a-kind event in Denver...

128 - Seattle Genetics to Present at UBS Global Life Sciences Conference

BOTHELL, Wash.-(Business Wire)-September 17, 2009 - Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 2009 UBS Global Life Sciences Conference on Tuesday, September 22, 2009, at 2:00 p.m. Eastern Time. The...

129 - Hythiam Raises Approximately $7 Million in Registered Direct Offering

LOS ANGELES-(Business Wire)-September 17, 2009 - Hythiam, Inc. (NASDAQ:HYTM) announced today that it has entered into definitive agreements to sell 9,333,334 shares of its common stock at a price per share of $.75 to institutional investors pursuant to a registered direct offering, representing...

130 - Medifocus, Inc. Files Response to its Investigational Device Exemption (IDE) With the Food and Drug Administration (FDA) in the United States for its Pivotal Phase III Clinical Trial for Treatment of Breast Cancer

VANCOUVER-(Business Wire)-September 17, 2009 - Medifocus, Inc. (TSXV:MFS) is pleased to announce that it has filed a comprehensive response to its IDE application with the FDA in the United States to obtain clearance to initiate a pivotal phase III clinical trial using the Company’s Microfocus APA...

131 - Research and Markets: PET/CT and SPECT/CT to Plan and Monitor the Treatment of Cancer

DUBLIN-(Business Wire)-September 17, 2009 - Research and Markets . The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the course...

132 - Calypso Medical Closes $50 Million Venture Financing Round

SEATTLE-(Business Wire)-September 17, 2009 - Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced the completion of a $50 million round of venture capital financing, led by Skyline Ventures and Frazier...

133 - Snapfish by HP Invites Consumers to “Share to Care” During Breast Cancer Awareness Month

PALO ALTO, Calif.-(Business Wire)-September 17, 2009 - Snapfish by HP (NYSE:HPQ), the No. 1 online photo service, today announced the launch of its 2009 “Share to Care” campaign in support of breast cancer awareness month. Throughout October, Snapfish will offer free “Share to Care” photo...

134 - ImmunoCellular Therapeutics’ Immunology Platform Featured in Report on the Future of Cancer Research

LOS ANGELES-(Business Wire)-September 17, 2009 - ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has been featured in an in-depth report by...

135 - EKR Therapeutics to Present at the 2009 UBS Global Life Sciences Conference

BEDMINSTER, N.J.-(Business Wire)-September 17, 2009 - EKR Therapeutics, Inc., a specialty pharmaceutical company focused on commercializing critical-care products for the hospital setting, today announced that Howard Weisman, CEO & President, will present at the UBS Global Life Sciences...

136 - Rexahn Pharmaceuticals and Teva Pharmaceutical Industries Agree to Close on a License Agreement

ROCKVILLE, Md.-(Business Wire)-September 17, 2009 - Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has reached an agreement to close on...

137 - Power3 Medical Products, Inc. Headlines Session at International Molecular Diagnostic Meeting in China

HOUSTON-(Business Wire)-September 17, 2009 - Power3 Medical Products, Inc. (OTCBB: PWRM), a leader in neurodegenerative disease and cancer biomarkers and diagnostic tests, announces further international recognition of validity as the company’s President and CSO, Dr. Ira Goldknopf, will deliver an...

138 - Meridian Health Receives CEO Cancer Gold StandardTM Accreditation

CARY, N.C.-(Business Wire)-September 17, 2009 - Meridian Health has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and...

139 - RiskMetrics Group – ISS Governance Services Recommends Stockholders Vote “FOR” BioSante and Cell Genesys Merger

LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 17, 2009 - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Cell Genesys, Inc. (NASDAQ: CEGE), today jointly announced that RiskMetrics Group – ISS Governance Services, a leading proxy advisory firm, has recommended...

140 - Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance

SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass.-(Business Wire)-September 17, 2009 - Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Biogen Idec (Nasdaq:BIIB), today announced that a Phase III study (PRIMA) showed that patients with follicular...

141 - ImmunoGen Announces Amgen has Licensed Rights to Use the Company’s TAP Technology for a Solid Tumor Target

WALTHAM, Mass.-(Business Wire)-September 16, 2009 - ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company’s maytansinoid Targeted Antibody Payload (TAP) technology to...

142 - ADAO Congratulates the Acting U.S. Surgeon General, Steven K. Galson, and Thanks the U.S. Senate for Efforts to Encourage Warning About Asbestos Dangers

REDONDO BEACH, Calif.-(Business Wire)-September 16, 2009 - The Asbestos Disease Awareness Organization (ADAO) today announced its support for the Surgeon General’s statement acknowledging the dangers of asbestos and thanks the U.S. Senate for continued efforts to encourage a warning. The discovery...

143 - Provectus Pharmaceuticals Will Present at the Maxim Group Growth Conference on September 29, 2009

KNOXVILLE, Tenn.-(Business Wire)-September 16, 2009 - Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, will present at the Maxim Group Growth Conference on September 29, 2009 at 9:00 a.m. Eastern Time. The conference will be held...

144 - Research and Markets: Skin Lymphoma - Can be Easily Misdiagnosed as Psoriasis or Dermatitis: The Illustrated Guide, 3rd Edition

DUBLIN-(Business Wire)-September 16, 2009 - Research and Markets . 8. Cutaneous small-medium pleomorphic T-cell lymphoma. 9. Other cutaneous T-cell lymphomas. SECTION 2. CUTANEOUS B-CELL LYMPHOMAS. 10. Cutaneous follicle centre lymphoma. 11. Cutaneous marginal zone lymphoma & variants. 12...

145 - Walk on National Mall in November to Benefit Lung Cancer Research

ARLINGTON, Va.-(Business Wire)-September 16, 2009 - A young Bethesda family is taking their personal battle with lung cancer to the National Mall in November, hosting a fundraising walk to benefit lung cancer research. Breathe Deep DC — a 5k walk on the National Mall on November 15th &mdash...

146 - iCAD Announces Educational Initiatives Focusing on New Prostate Imaging Technologies

NASHUA, N.H.-(Business Wire)-September 16, 2009 - iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announces a series of educational events designed for radiologists, urologists, oncologists...

147 - Metabolomics Used to Identify the Mechanism of Action of an Anti-Cancer Drug

RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 16, 2009 - Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced a new study has been published identifying the mechanism of action of the anti-cancer drug GMX1778. Co-authored by scientists at...

148 - Mentor Capital Cancer Immunotherapy Index Posts Second 20% Plus Monthly Gain Lead by ImmunoCellular Therapeutics

SAN DIEGO-(Business Wire)-September 16, 2009 - The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 58% in its first two months of reporting. CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (IMUC.OB) under the...

149 - Helicos BioSciences Corporation Announces Pricing of Common Stock and Warrant Private Placement

CAMBRIDGE, Mass.-(Business Wire)-September 16, 2009 - Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets, today announced that it has entered into a definitive agreement...

150 - Cyntellect Launches Stem Cell Manager™ Powered by LEAP™

SAN DIEGO-(Business Wire)-September 16, 2009 - Cyntellect, Inc., a privately-held life sciences company commercializing products to advance life science and stem cell research, biopharmaceutical production, and drug discovery, announced today the commercial availability of Stem Cell Manager...

151 - AVEO Pharmaceuticals Appoints William J. Slichenmyer, M.D., Sc.M., as Chief Medical Officer and Robert C. Young, M.D., to Board of Directors

CAMBRIDGE, Mass.-(Business Wire)-September 16, 2009 - AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of William J. Slichenmyer, M.D...

152 - Celsion’s ThermoDox® Study for RCW Breast Cancer Aired on ABC and CBS Affiliate Stations

COLUMBIA, Md.-(Business Wire)-September 16, 2009 - Celsion Corporation (NASDAQ:CLSN) announced today the Company’s DIGNITY clinical trial evaluating the use of ThermoDox® in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial...

153 - Spectrum Pharmaceuticals to Present at the UBS Global Life Sciences Conference

IRVINE, Calif.-(Business Wire)-September 16, 2009 - Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage biotechnology company with a focus in oncology, announced today that an overview of the Company’s business strategy will be presented at the UBS Global Life Sciences Conference...

154 - Aptuit, Inc. Receives CEO Cancer Gold StandardTM Accreditation

CARY, N.C.-(Business Wire)-September 16, 2009 - Aptuit, Inc. has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to the health of their employees and family members by certifying their efforts to meet an exceptionally high standard of cancer...

155 - Progenics Announces Promotion of Mark R. Baker to President and Appoints Him to Board of Directors

TARRYTOWN, N.Y.-(Business Wire)-September 16, 2009 - Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the promotion of Mark R. Baker to the newly created position of President. Mr. Baker was also appointed to the Board of Directors. He will continue to report to Paul J. Maddon, M.D...

156 - SuperGen to Present at Upcoming Investment Conferences

DUBLIN, Calif.-(Business Wire)-September 16, 2009 - SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., President and Chief Executive Officer, will present at two upcoming...

157 - Report from Elekta’s Annual Meeting 2009

STOCKHOLM, Sweden-(Business Wire)-September 15, 2009 - Regulatory News: At the Annual General Meeting of Elekta AB (publ), 60 shareholders entitled to vote participated, representing 52 percent of the votes in the company.• Dividend to shareholders of SEK 2.00 (1.75) per share.• Akbar Seddigh...

158 - PPD Opens Global Central Lab in Singapore

WILMINGTON, N.C.-(Business Wire)-September 15, 2009 - PPD, Inc. (Nasdaq: PPDI) today announced it has opened its global central lab facility in Singapore, strengthening its ability to provide biopharmaceutical clients an extensive range of customized laboratory services in Southeast Asia, a...

159 - Medifacts Presents Free Symposium on “Meeting the Evolving Cardiac Safety Requirements from Diabetes to Oncology” at the North Carolina Biotech Center

-(Business Wire)-September 15, 2009 - Medifacts International: Who:   Medifacts International, Jeff Heilbraun and Boaz Mendzelevski, MD   Title: Recognizing the Cardiac Safety Continuum; Meeting the Evolving Cardiac Safety Requirements for New Medicinal Entities from Diabetes to Oncology...

160 - Duraflame Goes Pink to Help Fight Breast Cancer

STOCKTON, Calif.-(Business Wire)-September 15, 2009 - Cozying up to a fire will take on new meaning this fall: supporting the fight against breast cancer. Duraflame (www.duraflame.com) is debuting a pink-packaged firelog this October for Breast Cancer Awareness Month. Two percent of the Pink...

161 - Array BioPharma to Present at the UBS Global Life Sciences Conference

BOULDER, Colo.-(Business Wire)-September 15, 2009 - Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the UBS Global Life Sciences Conference on September 21 in New York City. The public is welcome to participate in the conference...

162 - IntrinsiQ Study: Oncologists Overlook Maintenance Therapy Option – More Often than They Realize

WALTHAM, Mass.-(Business Wire)-September 15, 2009 - IntrinsiQ, the company improving the quality and understanding of cancer care, today announced the findings of the company’s first IntelliView 360™ research study. The biggest outcome: Oncologists believe they treat lung cancer patients in...

163 - Groundbreaking Breast Cancer Radiation Technique Delivers Proven Long-Term Benefits and Saves Lives

SUNNYVALE, Calif.-(Business Wire)-September 15, 2009 - One minute of radiation in the operating room (OR) could save the lives of thousands of women being treated for breast cancer in the US today. According to a growing body of research, a 60-second course of radiation therapy delivered during...

164 - Orange County Set to Race for the Cure®

COSTA MESA, Calif.-(Business Wire)-September 15, 2009 - Grab your running or walking shoes, don some pink and help make an impact by taking the new “125 Challenge” along with more than 30,000 activists and breast cancer survivors in the fight against breast cancer, the most prevalent cancer...

165 - Ray Stachowiak Elected to Board of Directors of American Shared Hospital Services

SAN FRANCISCO-(Business Wire)-September 15, 2009 - AMERICAN SHARED HOSPITAL SERVICES (NYSE AMEX:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that Ray Stachowiak has been elected to the Company's Board of...

166 - Elekta: Interim Report May – July 2009/10

STOCKHOLM-(Business Wire)-September 15, 2009 - Reglatory News: Elekta AB (publ) (STO:EKTAB): Order bookings rose 19* percent. Net sales increased by 15* percent. Operating profit rose to SEK 89 M (13). Profit after taxes increased to SEK 56 M (1). Earnings per share after dilution improved to SEK...

167 - Free Resource for Cancer Patients and Families in Tough Economic Times

APEX, N.C.-(Business Wire)-September 15, 2009 - The NavigateCancer Foundation (NCF), a nonprofit staffed by oncology professionals, provides patient advocacy tools and services for cancer patients and families, is filling an especially vital role as the ranks of the unemployed and uninsured steadily...

168 - Cytheris Announces Interim Data from INSPIRE Study Showing Interleukin-7 (CYT107) Induces Dose-Dependent and Sustained Increase of CD4 T Cells in Chronic HIV-Infected Patients

PARIS-(Business Wire)-September 15, 2009 - Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced presentation of data from an interim analysis of CLI-107-06 (INSPIRE), a Phase I/IIa study of HIV-infected...

169 - BioAlliance Pharma Makes Four Presentations at the 49th ICAAC Meeting Including Three Phase III Study Results with miconazole Lauriad® and One with Its Integrase Inhibitor

PARIS-(Business Wire)-September 15, 2009 - Regulatory News: BioAlliance Pharma has attended the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco to present results on miconazole Lauriad® and anti-integrase inhibitor. The results of a phase III...

170 - Breast Preservation Foundation Urges Washington Policymakers to Consider Public Health Education Programs in Health Care Reform Discussions

LOS ANGELES-(Business Wire)-September 14, 2009 - Amidst the ongoing health-policy debate, Los Angeles surgeon Joel Aronowitz, M.D., founder of the Breast Preservation Foundation, furthered his organization’s health education and quality of care mission by meeting Washington policymakers to discuss...

171 - Omnyx Announces the Award of a Digital Pathology Patent to Reduce Scan Times and Increase Image Quality

PITTSBURGH-(Business Wire)-September 14, 2009 - Omnyx, a joint venture of GE Healthcare and The University of Pittsburgh Medical Center, has announced the United States Patent and Trademark Office has issued patent no. 7576307 covering dual image sensors for rapid autofocusing. This technology...

172 - Research and Markets: Assess Ten-Year Test Volume and Sales Forecasts for 40 Cancer Diagnostic Procedures Performed in French Hospitals and Commercial Laboratories inside Latest Report

DUBLIN-(Business Wire)-September 14, 2009 - Research and Markets has announced the addition of the "The French Cancer Diagnostics Market" report to their offering. This report presents a comprehensive analysis of the French cancer diagnostics market, including: Major issues pertaining to the...

173 - ArQule, Inc. to Present at UBS Global Life Sciences Conference on September 21, 2009

WOBURN, Mass.-(Business Wire)-September 14, 2009 - ArQule, Inc. (Nasdaq: ARQL) today announced that it will present at the UBS Global Life Sciences Conference on Monday, September 21, 2009 at 10:30 a.m. eastern time. ArQule’s presentation will be web cast live and can be accessed through the...

174 - Quintiles Advances Cancer Treatment Through New Digital Pathology Services

RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 14, 2009 - Targeted Molecular Diagnostics (TMD), a Quintiles Central Laboratory, announced today the availability of digital pathology services in Beijing, China. The services add to Quintiles offerings used in the development of therapies to...

175 - RedPath Integrated Pathology, Inc. to Present at 3 Rivers Venture Fair

PITTSBURGH-(Business Wire)-September 14, 2009 - RedPath Integrated Pathology, Inc., a molecular diagnostics company dedicated to the effective diagnosis and treatment of cancer, today announced that Mark D. Myslinski, RedPath’s president and chief executive officer, will share his perspectives...

176 - University of Maryland Greenebaum Cancer Center the Latest Top Cancer Center to Adopt Calypso Medical’s “GPS for the Body” Tumor-Tracking Technology

SEATTLE-(Business Wire)-September 14, 2009 - Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, announced today that the University of Maryland Marlene and Stewart Greenebaum Cancer Center, a National Cancer...

177 - BioReference Laboratories, Inc to Speak at the UBS Global Life Sciences Conference

ELMWOOD PARK, N.J.-(Business Wire)-September 14, 2009 - BioReference Laboratories, Inc (NASDAQ:BRLI) announced today that Marc D. Grodman M.D., President and Chief Executive Officer, is scheduled to speak at the 2009 UBS Global Life Sciences Conference on Monday, September 21, 2009, at The Grand...

178 - PolyMedix to Make Three Presentations of Antibiotic Data at the 49Th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

RADNOR, Pa.-(Business Wire)-September 14, 2009 - PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, will make three presentations of clinical and...

179 - CytRx and Cephalon Oncology Therapies to be Evaluated as Treatment for Relapsed Acute Promyelocytic Leukemia

LOS ANGELES-(Business Wire)-September 14, 2009 - CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced the initiation of a dose escalation study with its oncology drug candidate tamibarotene combined...

180 - Research and Markets: The Spanish Cancer Diagnostics Market

DUBLIN-(Business Wire)-September 14, 2009 - Research and Markets has announced the addition of the "The Spanish Cancer Diagnostics Market" report to their offering. This report presents a comprehensive analysis of the Spanish cancer diagnostics market, including: Major issues pertaining to the...

181 - Celldex Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Trial of its CDX-1401 Cancer Vaccine Candidate

NEEDHAM, Mass.-(Business Wire)-September 14, 2009 - Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the first patient has been dosed in a Phase 1/2 study of its vaccine candidate, CDX-1401, in patients with malignant solid tumors that express NY-ESO-1. CDX-1401 is a fully human...

182 - ARIAD Announces Result of First Interim Analysis of Phase 3 Succeed Trial of Oral Ridaforolimus, Its Investigational mTOR Inhibitor, in Metastatic Sarcomas

CAMBRIDGE, Mass.-(Business Wire)-September 14, 2009 - ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the independent Data Monitoring Committee (DMC) of the Phase 3 SUCCEED trial has completed the first interim efficacy analysis as specified by the study protocol and has recommended...

183 - Celsion and the American Liver Foundation Partner to Promote Awareness of Primary Liver Cancer and the ThermoDox® Phase III Global HEAT Study to Patients and Physicians

COLUMBIA, Md. & NEW YORK-(Business Wire)-September 14, 2009 - Celsion Corporation (NASDAQ:CLSN) and the American Liver Foundation (ALF) announced today that they have formed a partnership to provide education to physicians and liver patients about the treatment options for hepatocellular...

184 - Research and Markets: A Comprehensive Analysis of the German Cancer Diagnostics Market

DUBLIN-(Business Wire)-September 14, 2009 - Research and Markets has announced the addition of the "The German Cancer Diagnostics Market" report to their offering. This report presents a comprehensive analysis of the German cancer diagnostics market, including: Major issues pertaining to the...

185 - GTx Announces Phase III Clinical Development of Toremifene 20 mg on Course Following Planned Safety Review

MEMPHIS, Tenn.-(Business Wire)-September 14, 2009 - GTx, Inc. (Nasdaq: GTXI), today announced that following a planned safety review, an independent Data Safety Monitoring Board (DSMB) has recommended that the company continue as planned the pivotal Phase III clinical trial evaluating toremifene...

186 - FDA and EMEA Grant Orphan Drug Designation for Antisense Pharma's Investigational Drug Trabedersen in Pancreatic Carcinoma

REGENSBURG, Germany-(Business Wire)-September 14, 2009 - The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received orphan drug designation from both the European Medicines Agency EMEA and the US Food and Drug Administration FDA for its investigational drug...

187 - 2009 Lasker Awards Honor Trailblazers in Medical Research and Public Service:

NEW YORK-(Business Wire)-September 14, 2009 - The Albert and Mary Lasker Foundation, which for 64 years has championed the greatest breakthroughs in medical research, today announced the winners of the 2009 Lasker Awards for outstanding accomplishments in basic medical and clinical medical research...

188 - Forest Laboratories Presents Analysis of Two Positive Pivotal Phase III Studies of Ceftaroline for the Treatment of Community-Acquired Pneumonia (CAP) at ICAAC

SAN FRANCISCO-(Business Wire)-September 12, 2009 - Forest Laboratories, Inc (NYSE: FRX) today presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco new data from a complete analysis of FOCUS 1 and FOCUS 2, two global multicenter Phase III...

189 - Citizens for Health to Hold Press Conference—“Living With Brain Tumors”—Monday, September 14th Immediately Following Senate Hearings on “The Health Effects of Cell Phones” Organized by Sen. Arlen Specter

WASHINGTON-(Business Wire)-September 12, 2009 - Citizens for Health (www.citizens.org) will host a press conference at approximately 4:15 p.m. on Monday, September 14th entitled “Living with Brain Cancer,” immediately following Senate hearings on “The Health Effects of Cell Phone Use...

190 - Research and Markets: Ovarian Cancer - A Concise Analysis of the Most Important Information About this Disease, its Treatment and Market Opportunities

DUBLIN-(Business Wire)-September 11, 2009 - Research and Markets III. SYMPTOMS AND DIAGNOSIS Symptoms Risk factors Diagnostic tests Staging of epithelial cancer IV. TREATMENT By stage for epithelial cancer Prevention Treatment for other forms of ovarian cancer V. DOSING AND TREATMENT COSTS VI...

191 - Research and Markets: The Japanese Cancer Diagnostics Market Features the Company Profiles and 40 Cancer Diagnostic Procedures

DUBLIN-(Business Wire)-September 11, 2009 - Research and Markets has announced the addition of the "The Japanese Cancer Diagnostics Market" report to their offering. This report presents a comprehensive analysis of the Japanese cancer diagnostics market, including: Major issues pertaining to the...

192 - Research and Markets: The US Cancer Diagnostics Market - Includes Mortality Statistics, Scientific Views, Sales Forecasts and Much More

DUBLIN-(Business Wire)-September 11, 2009 - Research and Markets has announced the addition of the "The US Cancer Diagnostics Market" report to their offering. This report presents a comprehensive analysis of the US cancer diagnostics market, including: Major issues pertaining to the US laboratory...

193 - Research and Markets: Prostate Cancer Therapy Area Pipeline Report: Status of Prostate Cancer Drugs by Company and by Stage and Summary of the Latest News and Developments

DUBLIN-(Business Wire)-September 11, 2009 - Research and Markets has announced the addition of the "Prostate Cancer Therapy Area Pipeline Report" report to their offering. Life Science Analytics, Prostate Cancer Therapy Area Pipeline Report contains detailed information on the prostate cancer drug...

194 - Research and Markets: Ovarian Cancer Therapy Area Pipeline Report

DUBLIN-(Business Wire)-September 11, 2009 - Research and Markets has announced the addition of the "Ovarian Cancer Therapy Area Pipeline Report" report to their offering. Life Science Analytics, Ovarian Cancer Therapy Area Pipeline Report contains detailed information on the ovarian cancer drug...

195 - GenSpera Receives FDA Approval for G-202 Phase I Cancer Trial

SAN ANTONIO-(Business Wire)-September 11, 2009 - GenSpera, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to begin a Phase I study with its target activated pro-drug, G-202, for the treatment of cancer. GenSpera’s...

196 - Research and Markets: A Comprehensive Analysis on the Italian Cancer Diagnostics Market

DUBLIN-(Business Wire)-September 11, 2009 - Research and Markets has announced the addition of the "The Italian Cancer Diagnostics Market" report to their offering. This report presents a comprehensive analysis of the Italian cancer diagnostics market, including: Major issues pertaining to the...

197 - Research and Markets: The UK Cancer Diagnostics Market Feature Ten-Year Test Volume and Sales Forecasts for 40 Cancer Diagnostic Procedures

DUBLIN-(Business Wire)-September 11, 2009 - Research and Markets has announced the addition of the "The UK Cancer Diagnostics Market" report to their offering. This report presents a comprehensive analysis of the UK cancer diagnostics market, including: Major issues pertaining to the UK laboratory...

198 - BioMarker Strategies Raises $1.7 Million, Including Investment by Abell Foundation

BALTIMORE-(Business Wire)-September 11, 2009 - BioMarker Strategies announced today that it has raised $1.7 million in a private placement funding round that occurred in conjunction with the Maryland Biotechnology Investment Incentive Tax Credit Program. BioMarker Strategies is developing the...

199 - IntrinsiQ President Speaks at ICORE Oncology Summit

WALTHAM, Mass.-(Business Wire)-September 11, 2009 - IntrinsiQ president Jeff Forringer will discuss clinical oncology treatment guidelines – and what drives variations from the standard-of-care – at the 6th Annual ICORE/Magellan Oncology Summit this Friday in New York. As the economics of...

200 - Millennium Initiates Phase II Trial of Prostate Cancer Compound

CAMBRIDGE, Mass.-(Business Wire)-September 11, 2009 - Takeda Pharmaceutical Company Limited (TSE:4502) and its wholly-owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of the Phase II portion of a Phase I/II clinical trial of TAK-700 in patients with advanced...

Search Our News Using Google Search

Can't find what you want? Try using Google:

	Enter your search terms Submit search form
	Web www.digital50.com

	Subscribe to our RSS feeds and get press releases delivered daily
	Subscribe to Business Press Releases in up to 210 Industries
	Add the DiGiTAL50 Search to your Site, FREE!